Amedeo Smart

Free Medical Literature Service


 

Amedeo

HIV Infection

  Free Subscription

06.11.2017

5 AIDS
3 AIDS Res Hum Retroviruses
2 Antimicrob Agents Chemother
9 Clin Infect Dis
1 Drugs
2 HIV Med
1 Int J Dermatol
9 J Acquir Immune Defic Syndr
1 J Clin Invest
1 J Immunol
3 J Infect Dis
1 J Med Virol
5 J Virol
2 Lancet Glob Health
3 Lancet HIV
1 Lancet Infect Dis
3 N Engl J Med
1 Pediatr Infect Dis J
20 PLoS One
3 PLoS Pathog
2 Proc Natl Acad Sci U S A
3 Vaccine
1 Virology



    AIDS

  1. THIEBAUT R, Hue S, Le Marec F, Lelievre JD, et al
    Serum suppression of tumorigenicity 2 level is an independent predictor of all-cause mortality in HIV-infected patients.
    AIDS. 2017;31:2355-2365.
    >> Share

  2. JOSEPH DAVEY DL, Wall KM
    Need to include couples' HIV counselling and testing as a strategy to improve HIV partner notification services.
    AIDS. 2017;31:2435-2436.
    >> Share

  3. DALAL S, Johnson C, Fonner V, Kennedy CE, et al
    Reaching people with undiagnosed HIV infection through assisted partner notification.
    AIDS. 2017;31:2436-2437.
    >> Share

  4. SAH P, Fitzpatrick MC, Pandey A, Galvani AP, et al
    HIV criminalization exacerbates subpar diagnosis and treatment across the United States: response to the 'Association of HIV diagnosis rates and laws criminalizing HIV exposure in the United States'.
    AIDS. 2017;31:2437-2439.
    >> Share


  5. Frailty in HIV infected people: a new risk factor for bone mineral density loss?: Erratum.
    AIDS. 2017;31:2441.
    >> Share


    AIDS Res Hum Retroviruses

  6. SAHA JM, Liu H, Hu PW, Nikolai BC, et al
    Proteomic profiling of a primary CD4+ T cell model of HIV-1 latency identifies proteins whose differential expression correlates with reactivation of latent HIV-1.
    AIDS Res Hum Retroviruses. 2017 Oct 30. doi: 10.1089/AID.2017.0077.
    >> Share

  7. CHAPLIN B, Imade GE, Onwuamah C, Odaibo G, et al
    Distinct pattern of TAMs with K65R in patients failing tenofovir-based antiretroviral therapy.
    AIDS Res Hum Retroviruses. 2017 Oct 30. doi: 10.1089/AID.2017.0198.
    >> Share

  8. NOLAN D, Rose RR, Rodriguez P, Salemi M, et al
    The spleen is an HIV-1 sanctuary during cART.
    AIDS Res Hum Retroviruses. 2017 Oct 30. doi: 10.1089/AID.2017.0254.
    >> Share


    Antimicrob Agents Chemother

  9. HERRERO-FERNANDEZ I, Pacheco YM, Genebat M, Rodriguez-Mendez MDM, et al
    Association between a suppressor combined antiretroviral therapy containing Maraviroc and the hepatitis B virus vaccine response.
    Antimicrob Agents Chemother. 2017 Oct 30. pii: AAC.02050.
    >> Share

  10. XIAO P, Gumber S, Marzinke MA, Date AA, et al
    Hypo-osmolar formulation of TFV enema promotes uptake and metabolism of TFV in tissues and leading to prevention of SHIV/SIV infection.
    Antimicrob Agents Chemother. 2017 Oct 30. pii: AAC.01644.
    >> Share


    Clin Infect Dis

  11. YAYA I, Costa M, Marcellin F, Miailhes P, et al
    Gender, alcohol use and fibrosis in HIV-HCV co-infected individuals.
    Clin Infect Dis. 2017 Oct 23. doi: 10.1093.
    >> Share

  12. BRUCE RD, Merlin J, Lum PJ, Ahmed E, et al
    2017 HIV Medicine Association of Infectious Diseases Society of America Clinical Practice Guideline for the Management of Chronic Pain in Patients Living With Human Immunodeficiency Virus.
    Clin Infect Dis. 2017;65:1601-1606.
    >> Share

  13. BALAJI AB, An Q, Smith JC, Newcomb ME, et al
    High HIV incidence and prevalence and associated factors among adolescent sexual minority males, 3 cities, 2015.
    Clin Infect Dis. 2017 Oct 24. doi: 10.1093.
    >> Share

  14. HUAMAN MA, Ticona E, Miranda G, Kryscio RJ, et al
    The Relationship between Latent Tuberculosis Infection and Acute Myocardial Infarction.
    Clin Infect Dis. 2017 Oct 21. doi: 10.1093.
    >> Share

  15. ZHAO Y, Wu Z, McGoogan JM, Shi CX, et al
    Immediate antiretroviral therapy decreases mortality among patients with high CD4 counts in China: a nationwide, retrospective cohort study.
    Clin Infect Dis. 2017 Oct 21. doi: 10.1093.
    >> Share

  16. DE LEDINGHEN V, Laforest C, Hezode C, Pol S, et al
    Retreatment with sofosbuvir plus grazoprevir/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed a NS5A or NS3-containing regimen. ANRS HC34 REVENGE.
    Clin Infect Dis. 2017 Oct 25. doi: 10.1093.
    >> Share

  17. SCHEER S, Hsu L, Schwarcz S, Pipkin S, et al
    Trends in the San Francisco HIV Epidemic in the "Getting to Zero" Era.
    Clin Infect Dis. 2017 Nov 1. doi: 10.1093.
    >> Share

  18. SCOTT N, Stoove M, Kelly SL, Wilson DP, et al
    Achieving 90-90-90 HIV targets will not be enough to achieve the HIV incidence reduction target in Australia.
    Clin Infect Dis. 2017 Nov 1. doi: 10.1093.
    >> Share

  19. MURNANE PM, Strehlau R, Shiau S, Patel F, et al
    Reply to van de Wijer et. al.
    Clin Infect Dis. 2017 Oct 23. doi: 10.1093.
    >> Share


    Drugs

  20. DEEKS ED
    Raltegravir Once-Daily Tablet: A Review in HIV-1 Infection.
    Drugs. 2017;77:1789-1795.
    >> Share


    HIV Med

  21. DE WIT S, Battegay M, D'Arminio Monforte A, Lundgren JD, et al
    European AIDS Clinical Society Second Standard of Care Meeting, Brussels 16-17 November 2016: a summary.
    HIV Med. 2017 Oct 27. doi: 10.1111/hiv.12559.
    >> Share

  22. AIBIBULA W, Cox J, Hamelin AM, Moodie E, et al
    Food insecurity may lead to incomplete HIV viral suppression and less immune reconstitution among HIV/hepatitis C virus-coinfected people.
    HIV Med. 2017 Nov 2. doi: 10.1111/hiv.12561.
    >> Share


    Int J Dermatol

  23. COSTA-SILVA M, Coutinho D, Sobrinho-Simoes J, Azevedo F, et al
    Cross-sectional study of Treponema pallidum PCR in diagnosis of primary and secondary syphilis.
    Int J Dermatol. 2017 Oct 31. doi: 10.1111/ijd.13823.
    >> Share


    J Acquir Immune Defic Syndr

  24. PATTERSON S, Carter A, Nicholson V, Webster K, et al
    Condomless Sex Among Virally Suppressed Women With HIV With Regular HIV-Serodiscordant Sexual Partners in the Era of Treatment as Prevention.
    J Acquir Immune Defic Syndr. 2017;76:372-381.
    >> Share

  25. SHARP A, O'Hagan R, Honermann B, Millett G, et al
    Setting Targets for HIV: An Evaluation of Indicator Quality and Target Achievement in National Strategic Plans.
    J Acquir Immune Defic Syndr. 2017;76:348-355.
    >> Share

  26. MARKOWITZ M, Grossman H, Anderson PL, Grant R, et al
    Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis.
    J Acquir Immune Defic Syndr. 2017;76:e104-e106.
    >> Share

  27. CABRAL A, Baeten J, Ngure K, Velloza J, et al
    Intimate partner violence and self-reported pre-exposure prophylaxis (PrEP) interruptions among HIV-negative partners in HIV serodiscordant couples in Kenya and Uganda.
    J Acquir Immune Defic Syndr. 2017 Oct 23. doi: 10.1097/QAI.0000000000001574.
    >> Share

  28. FRENCH AL, Martin JW, Evans CT, Peters M, et al
    Macrophage Activation and the Tumor Necrosis Factor Cascade in Hepatitis C Disease Progression Among HIV-Infected Women Participating in the Women's Interagency HIV Study.
    J Acquir Immune Defic Syndr. 2017;76:438-444.
    >> Share

  29. MAYER KH, Chan PA, Patel R, Flash CA, et al
    Evolving models and ongoing challenges for HIV pre-exposure prophylaxis implementation in the United States.
    J Acquir Immune Defic Syndr. 2017 Oct 27. doi: 10.1097/QAI.0000000000001579.
    >> Share

  30. MAZANDERANI AH, Moyo F, Kufa T, Sherman GG, et al
    Declining Baseline Viraemia and Escalating Discordant HIV-1 Confirmatory Results within South Africa's Early Infant Diagnosis Program, 2010-2016.
    J Acquir Immune Defic Syndr. 2017 Oct 27. doi: 10.1097/QAI.0000000000001581.
    >> Share

  31. FELLER DJ, Zucker J, Yin MT, Gordon P, et al
    Using Clinical Notes and Natural Language Processing for Automated HIV Risk Assessment.
    J Acquir Immune Defic Syndr. 2017 Oct 27. doi: 10.1097/QAI.0000000000001580.
    >> Share

  32. BRITES C, Abrahao M, Bozza P, Netto EM, et al
    Infection By Htlv-1 Is Associated With High Levels Of Pro-Inflammatory Cytokines, In Hiv-Hcv Coinfected Patients.
    J Acquir Immune Defic Syndr. 2017 Oct 27. doi: 10.1097/QAI.0000000000001576.
    >> Share


    J Clin Invest

  33. VEENHUIS RT, Freeman ZT, Korleski J, Cohen LK, et al
    HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells.
    J Clin Invest. 2017 Oct 30. pii: 95375. doi: 10.1172/JCI95375.
    >> Share


    J Immunol

  34. AROH C, Wang Z, Dobbs N, Luo M, et al
    Innate Immune Activation by cGMP-AMP Nanoparticles Leads to Potent and Long-Acting Antiretroviral Response against HIV-1.
    J Immunol. 2017 Oct 30. pii: ji1700972. doi: 10.4049/jimmunol.1700972.
    >> Share


    J Infect Dis

  35. VAN ZOEST RA, Underwood J, De Francesco D, Sabin CA, et al
    Structural brain abnormalities in successfully treated HIV infection: associations with disease and cerebrospinal fluid biomarkers.
    J Infect Dis. 2017 Oct 24. doi: 10.1093.
    >> Share

  36. KIRKEGAARD-KLITBO DM, Langkilde A, Mejer N, Andersen O, et al
    Soluble Urokinase Plasminogen Activator Receptor Is a Predictor of Incident Non-AIDS Comorbidity and All-Cause Mortality in Human Immunodeficiency Virus Type 1 Infection.
    J Infect Dis. 2017;216:819-823.
    >> Share

  37. NEWTON R, Labo N, Wakeham K, Miley W, et al
    Kaposi's sarcoma associated herpesvirus in a rural Ugandan cohort: 1992-2008.
    J Infect Dis. 2017 Nov 1. doi: 10.1093.
    >> Share


    J Med Virol

  38. SU S, Fairley CK, Sasadeusz J, He J, et al
    HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
    J Med Virol. 2017 Nov 1. doi: 10.1002/jmv.24988.
    >> Share


    J Virol

  39. MALHERBE DC, Mendy J, Vang L, Barnette PT, et al
    Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C SHIV Mucosal Challenge.
    J Virol. 2017 Nov 1. pii: JVI.01092-17. doi: 10.1128/JVI.01092.
    >> Share

  40. SOTO-NAVA M, Avila-Rios S, Valenzuela-Ponce H, Garcia-Morales C, et al
    Weaker HLA footprints on HIV in the unique and highly genetically admixed host population of Mexico.
    J Virol. 2017 Nov 1. pii: JVI.01128-17. doi: 10.1128/JVI.01128.
    >> Share

  41. PAROLINI F, Biswas P, Serena M, Sironi F, et al
    Stability and expression levels of HLA-C on the cell membrane modulate HIV-1 infectivity.
    J Virol. 2017 Oct 25. pii: JVI.01711-17. doi: 10.1128/JVI.01711.
    >> Share

  42. PAYNE EH, Ramalingam D, Fox DT, Klotman ME, et al
    Polyploidy And Mitotic Cell Death Are Two Distinct HIV-1 Vpr-Driven Outcomes In Renal Tubule Epithelial Cells.
    J Virol. 2017 Nov 1. pii: JVI.01718-17. doi: 10.1128/JVI.01718.
    >> Share

  43. ARACHCHIGE SP, Henke W, Pramanik A, Kalamvoki M, et al
    Analysis of Select HSV-1 Proteins for Restriction of Human Immunodeficiency Virus Type 1: The HSV-1 gM Protein Potently Restricts HIV-1 by Preventing the Intracellular Transport and Processing of Env gp160.
    J Virol. 2017 Nov 1. pii: JVI.01476-17. doi: 10.1128/JVI.01476.
    >> Share


    Lancet Glob Health

  44. LARNEY S, Peacock A, Leung J, Colledge S, et al
    Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review.
    Lancet Glob Health. 2017 Oct 23. pii: S2214-109X(17)30373.
    >> Share

  45. DEGENHARDT L, Peacock A, Colledge S, Leung J, et al
    Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.
    Lancet Glob Health. 2017 Oct 23. pii: S2214-109X(17)30375.
    >> Share


    Lancet HIV

  46. THE LANCET HIV
    U=U taking off in 2017.
    Lancet HIV. 2017;4:e475.
    >> Share

  47. LAZARUS JV, Barton SE, Bernardino JI
    Taking the long-view in a personalised approach to HIV care.
    Lancet HIV. 2017;4:e483-e485.
    >> Share

  48. NWOKOLO N, Hill A, McOwan A, Pozniak A, et al
    Rapidly declining HIV infection in MSM in central London.
    Lancet HIV. 2017;4:e482-e483.
    >> Share


    Lancet Infect Dis

  49. FORD N, Ball A, Baggaley R, Vitoria M, et al
    The WHO public health approach to HIV treatment and care: looking back and looking ahead.
    Lancet Infect Dis. 2017 Oct 20. pii: S1473-3099(17)30482.
    >> Share


    N Engl J Med

  50. BEYRER C, Pozniak A
    HIV Drug Resistance - An Emerging Threat to Epidemic Control.
    N Engl J Med. 2017;377:1605-1607.
    >> Share

  51. RICHARDSON HS, Eyal N, Campbell JI, Haberer JE, et al
    When Ancillary Care Clashes with Study Aims.
    N Engl J Med. 2017;377:1213-1215.
    >> Share

  52. GOMEZ-MOYANO E, Crespo-Erchiga V
    HIV Infection Manifesting as Proximal White Onychomycosis.
    N Engl J Med. 2017;377:e26.
    >> Share


    Pediatr Infect Dis J

  53. PINTO JA, Capparelli EV, Warshaw M, Zimmer B, et al
    A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines.
    Pediatr Infect Dis J. 2017 Oct 28. doi: 10.1097/INF.0000000000001817.
    >> Share


    PLoS One

  54. BUDHWANI H, Hearld KR, Hasbun J, Charow R, et al
    Transgender female sex workers' HIV knowledge, experienced stigma, and condom use in the Dominican Republic.
    PLoS One. 2017;12:e0186457.
    >> Share

  55. LAURENCE J, Elhadad S, Robison T, Terry H, et al
    HIV protease inhibitor-induced cardiac dysfunction and fibrosis is mediated by platelet-derived TGF-beta1 and can be suppressed by exogenous carbon monoxide.
    PLoS One. 2017;12:e0187185.
    >> Share

  56. ROVELLI C, Poli A, Galli L, Cernuschi M, et al
    Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males.
    PLoS One. 2017;12:e0186367.
    >> Share

  57. CINGOLANI A, Cozzi Lepri A, Teofili L, Galli L, et al
    Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population.
    PLoS One. 2017;12:e0186549.
    >> Share

  58. CHKHARTISHVILI N, Chokoshvili O, Bolokadze N, Tsintsadze M, et al
    Late presentation of HIV infection in the country of Georgia: 2012-2015.
    PLoS One. 2017;12:e0186835.
    >> Share

  59. FERNANDES JR, Berthoud TK, Kumar A, Angel JB, et al
    IL-23 signaling in Th17 cells is inhibited by HIV infection and is not restored by HAART: Implications for persistent immune activation.
    PLoS One. 2017;12:e0186823.
    >> Share

  60. MEYER-RATH G, Johnson LF, Pillay Y, Blecher M, et al
    Changing the South African national antiretroviral therapy guidelines: The role of cost modelling.
    PLoS One. 2017;12:e0186557.
    >> Share

  61. PEREZ-PARRA S, Chueca N, Alvarez M, Pasquau J, et al
    High prevalence and diversity of HIV-1 non-B genetic forms due to immigration in southern Spain: A phylogeographic approach.
    PLoS One. 2017;12:e0186928.
    >> Share

  62. ROZERA G, Fabbri G, Lorenzini P, Mastrorosa I, et al
    Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals.
    PLoS One. 2017;12:e0187095.
    >> Share

  63. REIGER S, Jardim TV, Abrahams-Gessel S, Crowther NJ, et al
    Awareness, treatment, and control of dyslipidemia in rural South Africa: The HAALSI (Health and Aging in Africa: A Longitudinal Study of an INDEPTH Community in South Africa) study.
    PLoS One. 2017;12:e0187347.
    >> Share

  64. WALL EC, Mukaka M, Denis B, Mlozowa VS, et al
    Goal directed therapy for suspected acute bacterial meningitis in adults and adolescents in sub-Saharan Africa.
    PLoS One. 2017;12:e0186687.
    >> Share

  65. MEYER-RATH G, van Rensburg C, Larson B, Jamieson L, et al
    Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case.
    PLoS One. 2017;12:e0186496.
    >> Share

  66. WU J, Crawford FW, Raag M, Heimer R, et al
    Using data from respondent-driven sampling studies to estimate the number of people who inject drugs: Application to the Kohtla-Jarve region of Estonia.
    PLoS One. 2017;12:e0185711.
    >> Share

  67. PROTIERE C, Spire B, Mora M, Poizot-Martin I, et al
    Patterns of patient and healthcare provider viewpoints regarding participation in HIV cure-related clinical trials. Findings from a multicentre French survey using Q methodology (ANRS-APSEC).
    PLoS One. 2017;12:e0187489.
    >> Share

  68. HANSOTI B, Kelen GD, Quinn TC, Whalen MM, et al
    A systematic review of emergency department based HIV testing and linkage to care initiatives in low resource settings.
    PLoS One. 2017;12:e0187443.
    >> Share

  69. WESSELS JM, Lajoie J, Vitali D, Omollo K, et al
    Association of high-risk sexual behaviour with diversity of the vaginal microbiota and abundance of Lactobacillus.
    PLoS One. 2017;12:e0187612.
    >> Share

  70. SMITH RL, Tan JME, Jonker MJ, Jongejan A, et al
    Beyond the polymerase-gamma theory: Production of ROS as a mode of NRTI-induced mitochondrial toxicity.
    PLoS One. 2017;12:e0187424.
    >> Share

  71. BABO YD, Alemie GA, Fentaye FW
    Predictors of first-line antiretroviral therapy failure amongst HIV-infected adult clients at Woldia Hospital, Northeast Ethiopia.
    PLoS One. 2017;12:e0187694.
    >> Share

  72. VINNARD C, Ravimohan S, Tamuhla N, Pasipanodya J, et al
    Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation.
    PLoS One. 2017;12:e0187624.
    >> Share

  73. ISNARD BAGNIS C, Pieroni L, Inaoui R, Maksud P, et al
    Impact of lean mass and bone density on glomerular filtration rate estimation in people living with HIV/AIDS.
    PLoS One. 2017;12:e0186410.
    >> Share


    PLoS Pathog

  74. BAILEY AL, Buechler CR, Matson DR, Peterson EJ, et al
    Pegivirus avoids immune recognition but does not attenuate acute-phase disease in a macaque model of HIV infection.
    PLoS Pathog. 2017;13:e1006692.
    >> Share

  75. MCBRIDE JA, Striker R
    Imbalance in the game of T cells: What can the CD4/CD8 T-cell ratio tell us about HIV and health?
    PLoS Pathog. 2017;13:e1006624.
    >> Share

  76. RATO S, Rausell A, Munoz M, Telenti A, et al
    Single-cell analysis identifies cellular markers of the HIV permissive cell.
    PLoS Pathog. 2017;13:e1006678.
    >> Share


    Proc Natl Acad Sci U S A

  77. MENGISTU M, Tang AH, Foulke JS Jr, Blanpied TA, et al
    Patterns of conserved gp120 epitope presentation on attached HIV-1 virions.
    Proc Natl Acad Sci U S A. 2017 Oct 30. pii: 201705074.
    >> Share

  78. DESHMUKH L, Tugarinov V, Louis JM, Clore GM, et al
    Binding kinetics and substrate selectivity in HIV-1 protease-Gag interactions probed at atomic resolution by chemical exchange NMR.
    Proc Natl Acad Sci U S A. 2017 Oct 30. pii: 201716098.
    >> Share


    Vaccine

  79. SHIRATSUCHI T, Rai U, Kaneko I, Zhang M, et al
    A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII.
    Vaccine. 2017 Oct 28. pii: S0264-410X(17)31474.
    >> Share

  80. FROTA ACC, Ferreira B, Harrison LH, Pereira GS, et al
    Safety and immune response after two-dose meningococcal C conjugate immunization in HIV-infected children and adolescents in Rio de Janeiro, Brazil.
    Vaccine. 2017 Oct 31. pii: S0264-410X(17)31451.
    >> Share

  81. SLEZAK J, Meyer K, Sy LS, Chao C, et al
    An imputation method for calculating and comparing autoimmune disease incidence using partial case review.
    Vaccine. 2017 Oct 24. pii: S0264-410X(17)31418.
    >> Share


    Virology

  82. DIAZ F, Gregory S, Nakashima H, Viapiano MS, et al
    Intramuscular delivery of replication-defective herpes simplex virus gives antigen expression in muscle syncytia and improved protection against pathogenic HSV-2 strains.
    Virology. 2017;513:129-135.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016